Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > New Press Release - Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations
View:
Comment by forhandlaren on Mar 13, 2024 9:35am
The last minute transparency is crucial to maintain the trust that is left at this stage. I like the strategy to distribute samples to stakeholders - why not send it my way as well! Let's get rid of the CEO and secure the funds needed to execute the rollout.
Comment by tylerreddick on Mar 13, 2024 10:30am
AbbVie was supposed to be providing the cash flow for general operational expenses. Too bad that appears to be another R&F fiasco.
Comment by MirrorWorldMan on Mar 13, 2024 11:17am
I remember a series of these press releases over the years where Howie is so proud to put a cream into a tube, non news.   He is scared of shrinking price and volumes and thought a NR would help. Useless, only financial data on Allergan deal will help.  Any internal metrics mean squat. 
Comment by biorun on Mar 13, 2024 1:06pm
You can't lay a golden egg until you have a chicken. The fact that they will have a production ready product they can table drop in front of a stakeholder is MASSIVE.  Speculation happens before realization. Forward earnings potential is what will be assessed here, and if others see it then the stock price will go up.
Comment by tylerreddick on Mar 13, 2024 1:12pm
More pointless word salad. What about 1067 that you pumped endlessly?
Comment by biorun on Mar 13, 2024 2:11pm
1067 my good buddy is licensed globally and with an organization far more competent and resources than Sirona to bring to market. Like I said, if one believes that Allergan will get to market, then 8 cents is a bargain, if you don't well then 8 cents is a fair assessment. As for you, you keep promising to put me on ignore but you simply can't stick to your word. How about you start now?
Comment by tylerreddick on Mar 13, 2024 3:50pm
You will note that I hadn't responded to your drivel for quite some time, as I did have you on ignore. I took you off today just to see if anything has changed, and no, it hasn't. All you post is mindless word salad. And you don't support the share price with buying, even when it is "cheap" in your "expert" opinion.  So yes, you can quite easily go back on ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities